Rheumatology

Back to articles

Rheumatoid arthritis update: Tocilizumab superior to adalimumab as monotherapy

KEY POINT

Monotherapy with the disease modifying antirheumatic drug (DMARD) tocilizumab (Actemra—Genentech) was superior to monotherapy with adalimumab (Humira—AbbVie) for improving the signs and symptoms of rheumatoid arthritis (RA) in patients intolerant to the non-biological DMARD methotrexate.